Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 26-50 of 66 citing articles:

IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study
Linong Ji, Hongwei� Jiang, Pei An, et al.
EClinicalMedicine (2021) Vol. 39, pp. 101088-101088
Open Access | Times Cited: 41
A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes
Hongwei� Jiang, Shuguang Pang, Yawei Zhang, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 33
Future therapies for obesity
Eka Melson, Alexander D. Miras, Dimitris Papamargaritis
Clinical Medicine (2023) Vol. 23, Iss. 4, pp. 337-346
Open Access | Times Cited: 19
MASLD treatment—a shift in the paradigm is imminent
Mariana Verdelho Machado
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 18
Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials
David Lubasi Nalisa, Nelson Cuboia, Eman Dyab, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 6
Glucagon agonism in the treatment of metabolic diseases including type 2 diabetes mellitus and obesity
Jonathan Brix Winther, Jens J. Holst
Diabetes Obesity and Metabolism (2024)
Open Access | Times Cited: 6
The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines
Sten Madsbad, Jens J. Holst
Expert Opinion on Investigational Drugs (2025), pp. 1-19
Open Access
Obesity pharmacotherapy: incretin action in the central nervous system
Geke Aline Boer, Debbie L. Hay, Alexander Tups
Trends in Pharmacological Sciences (2022) Vol. 44, Iss. 1, pp. 50-63
Closed Access | Times Cited: 21
Structural analysis of the dual agonism at GLP-1R and GCGR
Yang Li, Qingtong Zhou, Antao Dai, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 33
Open Access | Times Cited: 12
Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high‐dose GLP‐1 receptor agonists and GLP‐1 receptor‐based co‐agonists
Ronald Goldenberg, Jeremy Gilbert, Priya Manjoo, et al.
Obesity Reviews (2023) Vol. 25, Iss. 3
Closed Access | Times Cited: 12
Novel Therapeutics for Type 2 Diabetes Mellitus—A Look at the Past Decade and a Glimpse into the Future
Ying Jie Chee, Rinkoo Dalan
Biomedicines (2024) Vol. 12, Iss. 7, pp. 1386-1386
Open Access | Times Cited: 4
Innovative Drugs First Implemented in Type 2 Diabetes Mellitus and Obesity and Their Effects on Metabolic Dysfunction-Associated Steatohepatitis (MASH)-Related Fibrosis and Cirrhosis
Georgiana-Diana Cazac, C.M. Lǎcǎtusu, Elena-Daniela Grigorescu, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 4, pp. 1042-1042
Open Access
Focus on Glucagon-like Peptide-1 Target: Drugs Approved or Designed to Treat Obesity
Jiahua Zhang, Jintao Wei, Weiwen Lai, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 4, pp. 1651-1651
Open Access
Future Perspectives in the Management of Obesity
Shilpa Chugh Garcha, Sanjay Kalra
(2025), pp. 121-154
Closed Access
ANTI-OBESITY MEDICATIONS IN ADULT AND PEDIATRIC OBESITY AND METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE
Natalie Rodríguez, Phillipp Hartmann
Pharmacological Reviews (2025), pp. 100058-100058
Open Access
Efficacy of Liraglutide for Weight Loss in Overweight and Obese Non-diabetic Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Néstor Israel Quinapanta Castro, Miriam Marques de Almeida, Andres F Orbea, et al.
Cureus (2025)
Open Access
Emerging roles of oxyntomodulin-based glucagon-like peptide-1/glucagon co-agonist analogs in diabetes and obesity
Zhihong Yao, Wang Chen, Zhu Qianqian, et al.
Peptides (2023) Vol. 162, pp. 170955-170955
Closed Access | Times Cited: 10
Mechanisms of action of incretin receptor based dual- and tri-agonists in pancreatic islets
Franco Folli, Giovanna Finzi, Roberto Manfrini, et al.
AJP Endocrinology and Metabolism (2023) Vol. 325, Iss. 5, pp. E595-E609
Open Access | Times Cited: 9
The role of incretin receptor agonists in the treatment of obesity
Thomas Först, Christophe De Block, Stefano Del Prato, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 10, pp. 4178-4196
Open Access | Times Cited: 3
GLP-1-based therapies for the treatment of resistant hypertension in individuals with overweight or obesity: a review
Candace Jarade, Tetiana Zolotarova, Areesha Moiz, et al.
EClinicalMedicine (2024) Vol. 75, pp. 102789-102789
Open Access | Times Cited: 3
Glucagon-based therapy for people with diabetes and obesity: What is the sweet spot?
Emma Rose McGlone, Tricia Tan
Peptides (2024) Vol. 176, pp. 171219-171219
Open Access | Times Cited: 2
The current significance and prospects for the use of dual receptor agonism GLP-1/Glucagon
Renata Spezani, Carlos Alberto Mandarim‐de‐Lacerda
Life Sciences (2021) Vol. 288, pp. 120188-120188
Open Access | Times Cited: 17
Glucagon receptor antagonism impairs and glucagon receptor agonism enhances triglycerides metabolism in mice
Katrine D. Galsgaard, Emilie Elmelund, Christian D. Johansen, et al.
Molecular Metabolism (2022) Vol. 66, pp. 101639-101639
Open Access | Times Cited: 11
GLP-1/GIP/glucagon receptor triagonism gets its try in humans
Brian Finan, Jonathan D. Douros
Cell Metabolism (2022) Vol. 34, Iss. 1, pp. 3-4
Open Access | Times Cited: 9
Incretin-based therapy: a new horizon in diabetes management
Malek Zarei, Navideh Sahebi Vaighan, Mohammad Hadi Farjoo, et al.
Journal of Diabetes & Metabolic Disorders (2024) Vol. 23, Iss. 2, pp. 1665-1686
Closed Access | Times Cited: 1

Scroll to top